Extracellular matrix collagen remodeling predicts resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic paradigm for mismatch repair-deficient endometrial cancer (MMRd EC). However, a considerable subset of patients fails to achieve durable clinical benefit. This pronounced interpatient variability underscores the urgent unmet need for mechanistic predictive biomarkers beyond MMRd status alone to guide clinical decision-making.